The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
暂无分享,去创建一个
G. Prud’homme | E. Beshay | F. Croze | France Croze | Gerald J. Prud'homme | F. Croze | G. J. Prud'homme
[1] Roland Martin,et al. Therapeutic Potential of Phosphodiesterase-4 and -3 Inhibitors in Th1-Mediated Autoimmune Diseases , 2000, The Journal of Immunology.
[2] J. Koistinaho,et al. Molecular cloning and characterization of the rat inducible nitric oxide synthase (iNOS) gene. , 1999, Gene.
[3] G. Prud’homme,et al. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein , 1999, Gene Therapy.
[4] G. Prud’homme,et al. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. , 1998, Diabetes.
[5] A. Namboodiri,et al. Increasing cAMP Attenuates Induction of Inducible Nitric-oxide Synthase in Rat Primary Astrocytes* , 1997, The Journal of Biological Chemistry.
[6] J. Mountz,et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. , 1996, Journal of immunology.
[7] J. Cohen,et al. Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and IFN-gamma. , 1996, Journal of immunology.
[8] A. Hatzelmann,et al. PDE isoenzymes as targets for anti-asthma drugs. , 1995, The European respiratory journal.
[9] T. Greten,et al. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. , 1995, International journal of immunopharmacology.
[10] A. Fontana,et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis , 1995, Nature Medicine.
[11] M. Müller,et al. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL‐lpr/lpr mice , 1995, Journal of leukocyte biology.
[12] M. Netea,et al. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. , 1995, The Journal of infectious diseases.
[13] A. Grabowska,et al. Effect of pentoxifylline on nitric oxide released by murine macrophages. , 1995, Biology of the neonate.
[14] E. Leiter,et al. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. , 1994, Current opinion in immunology.
[15] C. Lowenstein,et al. Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.
[16] C. Weber,et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. , 1993, Journal of immunology.
[17] Y. Aragane,et al. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. , 1993, The Journal of investigative dermatology.
[18] F. Liew,et al. Nitric oxide production by murine macrophages is inhibited by prolonged elevation of cyclic AMP. , 1993, Biochemical and biophysical research communications.
[19] C. Thiemermann,et al. Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock , 1993, British journal of pharmacology.
[20] B. Fleischer,et al. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats , 1993, European journal of immunology.
[21] M. Mcdaniel,et al. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Snyder,et al. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] M. Mcdaniel,et al. Does Nitric Oxide Mediate Autoimmune Destruction of β-Cells?: Possible Therapeutic Interventions in IDDM , 1992, Diabetes.
[24] H. Kolb,et al. Cytotoxic action of IL‐1β against pancreatic islets is mediated via nitric oxide formation and is inhibited by N G‐monomethyl‐l‐arginine , 1992, FEBS letters.
[25] M. Mcdaniel,et al. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion. , 1991, The Journal of biological chemistry.
[26] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[27] T. Billiar,et al. Effect of exogenous and endogenous nitric oxide on mitochondrial respiration of rat hepatocytes. , 1991, The American journal of physiology.
[28] I. Green,et al. Inhibition of insulin secretion by interleukin‐1β and tumour necrosis factor‐α via an L‐arginine‐dependent nitric oxide generating mechanism , 1990 .
[29] G. Wilding,et al. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. , 1990, Analytical biochemistry.
[30] T. Seemayer,et al. Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages , 1984, The Journal of experimental medicine.